RecruitingNCT07610473
DT-101 compared with placebo for depression
About this title
Read the official source — NCT07610473This study evaluates the safety and effectiveness of DT-101 for people with depression.
Medication studyAges 18–75United States
Understand this study
What is this study about?
This study evaluates the safety and effectiveness of DT-101 for people with depression.
Who could participate?
This study is for people with depression. Listed age limits: 18 years to 75 years. Other eligibility criteria apply.
What will I do during this study?
After screening, participants are randomly assigned to DT-101 or placebo (an inactive comparison treatment). Over the following eight weeks, the study includes health checks, physical and neurological examinations, clinical assessments, questionnaires, and blood and urine samples. Additional blood samples are used to study how DT-101 is absorbed and processed by the body.
- Listed locations
- Phoenix and 22 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: May 14, 2026
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 118
- Sponsor
- Draig Therapeutics Ltd
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 75 Years
- Official registry ID
- NCT07610473
- Official title
Show the full official title
A Phase 2 Double-blind, Randomised, Placebo-controlled Trial to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of DT-101 in Adults With Major Depressive Disorder Receiving Pharmacological Therapy for Depression
Recruitment & locations
RecruitingPhoenix · Little Rock · Bellflower
17 more locations
- Costa Mesa
- Lafayette
- Hialeah
- Orlando
- Tampa
- Decatur
- Chicago
- Skokie
- Boston
- New York
- Columbus
- Allentown
- Media
- DeSoto
- Fort Worth
- Bellevue
- Seattle
A listed location does not confirm current availability.
Questions about this study
What is this study about?
This study evaluates the safety and effectiveness of DT-101 for people with depression.
Who is behind this study?
The study sponsor is Draig Therapeutics Ltd.
Does this study involve medication?
Yes. The study involves medication, including DT-101 and Placebo.
Who can participate?
This study is for people with depression. Listed age limits: 18 years to 75 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as recruiting.
